Molecular Tumour Boards
Molecular Tumour Boards provide a forum for health professionals to discuss the results of an individual patient’s comprehensive genome profile and to develop consensus interpretation or ‘matching’ of potential therapies based on the gene variants identified.
This information is then incorporated into decision-making around the best treatment options for individual patients, and supports the development of a tailored cancer management plan to achieve the best possible outcome.
MPCCC conducts regular Molecular Tumour Boards in the following tumour streams:
Haematological (blood) cancers
• Acute Myeloid Leukaemia and Minimal Residual Disease
• Myeloproliferative Neoplasms
• NEW: Rare cancers and Cancer of Unknown Primary (CUP)
• NEW: Pancreatic and Upper Gastrointestinal Cancers
• NEW: Melanoma
Each MPCCC Molecular Tumour Board is convened by a Chairperson. Patients cased are referred for discussion by the treating doctor, with the patient’s consent. Where possible, videoconferencing is used so that attending health professionals can dial in from remote locations.
To uphold patient confidentiality, Molecular Tumour Board are closed meetings and are only attended by a team of relevant medical professionals, including medical oncologists, radiation oncologists, surgeons, molecular and anatomical pathologists, cancer care nurses, research nurses, clinician researchers as well as medical specialists specific to the cancer type (e.g.) gastroenterologists for Upper Gastrointestinal and hepatobiliary cancers, lung/respiratory physicians for lung cancer and dermatologists for skin cancers.
For further information, please contact Sarah Mwaba via Sarah.Mwaba@monash.edu